Concurrent TP53 and CDKN2A Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy

Mantle cell lymphoma (MCL) is a subtype of B-cell lymphoma with a large number of recurrent cytogenetic/molecular aberrations. Approximately 5–10% of patients do not respond to frontline immunochemotherapy. Despite many useful prognostic indexes, a reliable marker of chemoresistance is not available...

Descripción completa

Detalles Bibliográficos
Autores principales: Malarikova, Diana, Berkova, Adela, Obr, Ales, Blahovcova, Petra, Svaton, Michael, Forsterova, Kristina, Kriegova, Eva, Prihodova, Eva, Pavlistova, Lenka, Petrackova, Anna, Zemanova, Zuzana, Trneny, Marek, Klener, Pavel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466084/
https://www.ncbi.nlm.nih.gov/pubmed/32751805
http://dx.doi.org/10.3390/cancers12082120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466084/
https://www.ncbi.nlm.nih.gov/pubmed/32751805
http://dx.doi.org/10.3390/cancers12082120

Ejemplares similares